Ayling Ruth M, Cotter Finbarr
Clinical Biochemistry, Barts Health NHS Trust, London, UK
Haemato-oncology, Barts Health NHS Trust, London, UK.
BMJ Open Gastroenterol. 2024 Sep 16;11(1):e001372. doi: 10.1136/bmjgast-2024-001372.
Colorectal cancer (CRC) is the fourth most common cancer in the UK. Patients with symptoms suggestive of CRC should be referred for urgent investigation. However, gastrointestinal symptoms are often non-specific and there is a need for suitable triage tools to enable prioritisation of investigations. In this study, the performance of the faecal immunochemical test (FIT), anaemia and the artificial intelligence algorithm ColonFlag were retrospectively examined and evaluated for their potential clinical benefits in patients who had been referred on an urgent lower gastrointestinal cancer pathway.
All patients aged over 40 years referred in a 12-month period were included. After 6 months, clinical outcomes were determined and the performance of the triage tests was evaluated.
A total of 3822 patients completed investigations and received a diagnosis. 143 had CRC, 126 high-risk adenomas (HRA). ColonFlag would have missed 27 CRC and 29 HRA. Faecal haemoglobin (f-Hb) at a cut-off of 10 µg/g would have missed 10 CRC and 26 HRA; f-Hb in combination with anaemia would have missed 2 CRC and 14 HRA. Using f-Hb in combination with ColonFlag would have missed only 1 CRC and 5 HRA and would have reduced the need for urgent referral by over 400 patients.
ColonFlag has potential to assist detection of CRC and HRA, alone where no faecal sample is present and in combination with FIT and to reduce the need for urgent referral.
结直肠癌(CRC)是英国第四大常见癌症。有结直肠癌疑似症状的患者应被转诊进行紧急检查。然而,胃肠道症状往往不具有特异性,因此需要合适的分诊工具来确定检查的优先级。在本研究中,回顾性检查并评估了粪便免疫化学检测(FIT)、贫血和人工智能算法ColonFlag在通过紧急下消化道癌症路径转诊的患者中的潜在临床益处。
纳入在12个月内转诊的所有40岁以上患者。6个月后,确定临床结果并评估分诊检测的性能。
共有3822名患者完成检查并得到诊断。其中143例患有结直肠癌,126例患有高危腺瘤(HRA)。ColonFlag会漏诊27例结直肠癌和29例高危腺瘤。粪便血红蛋白(f-Hb)临界值设为10μg/g时会漏诊10例结直肠癌和26例高危腺瘤;f-Hb与贫血联合使用会漏诊2例结直肠癌和14例高危腺瘤。将f-Hb与ColonFlag联合使用只会漏诊1例结直肠癌和5例高危腺瘤,并且会减少400多名患者的紧急转诊需求。
ColonFlag有潜力辅助检测结直肠癌和高危腺瘤,在没有粪便样本时单独使用,以及与粪便免疫化学检测联合使用时,并可减少紧急转诊的需求。